Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of...

  • Tuesday, October 11, 2011, 12:18 PM ET
    A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of Propofol, marking the third verdict against Baxter International (BAX -1.2%) and Teva Pharmaceuticals (TEVA +0.7%) over an outbreak in the state tied to use of the drug. An attorney for Teva passes off blame to doctors: "It’s not a vial problem... it’s a practice problem."
Track new comments on this story

This news story has 1 comment:

  •  
    The story is incomplete, the jury is awarding 100's of millions of dollars to patients. I was an anesthesiologist for 30 years and Propofol was never in reusable vials. The jury had a chance to stick it to big business and they did. They should have stuck it to the anesthetist who was unaware of the germ theory of disease.
    11 Oct 2011, 02:51 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »